CD4 remains the best measurement of a patient's immune and clinical status, identifying those at risk of Opportunistic Infections (OI), and supporting diagnostic decision-making, particularly for patients living with advanced HIV disease.
VISITECT® CD4 Advanced Disease is a rapid, semi-quantitative lateral flow assay for the estimation of CD4 protein on the surface of CD4+ T cells in human whole blood that indicates whether the level is above or below 200 cells/μL. It can be used in decentralised settings at the point-of-care or primary healthcare level.